Twenty-Four-Hour Heart Rate Lowering with Ivabradine in Chronic Heart Failure: Insights from the SHIFT Holter Substudy
Open Access
- 20 March 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 17 (5) , 518-526
Abstract
Aims Analysis of 24‐h Holter recordings was a pre‐specified substudy of SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial) for exploring the heart rhythm safety of ivabradine and to determine effects of ivabradine on 24‐h, daytime, and night‐time heart rate (HR) compared with resting office HR. Methods and results The 24‐h Holter monitoring was performed at baseline and 8 months after randomization to ivabradine (n = 298) or matching placebo (n = 304) titrated maximally to 7.5 mg b.i.d. in patients with baseline HR ≥70 b.p.m. Patients received guideline‐based optimized heart failure therapy including ACE inhibitors and/or ARBs in 93% and beta‐blockers at maximally tolerated doses in 93%. After 8 months, HR over 24 h decreased by 9.5 ± 10.0 b.p.m. with ivabradine, from 75.4 ± 10.3 b.p.m. (P < 0.0001), and by 1.2 ± 8.9 b.p.m. with placebo, from 74.8 ± 9.7 b.p.m. (P < 0.0001 for difference vs. ivabradine). HR reduction with ivabradine was similar in resting office and in 24‐h, awake, and asleep recordings, with beneficial effects on HR variability and no meaningful increases in supraventricular or ventricular arrhythmias. At 8 months, 21.3% on ivabradine vs. 8.5% on placebo had ≥1 episode of HR P < 0.0001). No episode of HR 2.5 s on ivabradine vs. 4 (1.6%) patients on placebo. No RR intervals >3 s were identified in patients taking ivabradine. Conclusion Ivabradine safely and significantly lowers HR and improves HR variability in patients with systolic heart failure, without inducing significant bradycardia, ventricular arrhythmias, or supraventricular arrhythmias.Keywords
Funding Information
- Servier
This publication has 33 references indexed in Scilit:
- Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudyEuropean Heart Journal, 2011
- Safety of Ivabradine in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction (from the BEAUTIFUL Holter Substudy)The American Journal of Cardiology, 2011
- Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trialThe Lancet, 2010
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Hospitalizations After Heart Failure DiagnosisJACC, 2009
- Predictive value of ambulatory heart rate in the Japanese general population: the Ohasama studyJournal Of Hypertension, 2008
- Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagenAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Changes in Heart Rate Variability Are Correlated to Hemodynamic Improvement With Chronic CARVEDILOL Therapy in Heart FailureJournal of Cardiac Failure, 2005
- Heart Rate Lowering by Specific and Selective If Current Inhibition with IvabradineDrugs, 2004
- Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery diseaseThe American Journal of Cardiology, 1992